Max S.Z. Zwartjes

Dr. Max S.Z. Zwartjes

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
MZMax S.Z. Zwartjes
Max S.Z. Zwartjes
VGVictor Gerdes
Victor Gerdes
MNmax Nieuwdorp
max Nieuwdorp
Obesity is becoming an increasing problem worldwide and is often, but not invariably, associated with dyslipidemia. The gut microbiota is increasingly linked to cardiovascular disease, nonalcoholic fatty liver disease, and type 2 diabetes mellitus. However, relatively little focus has been attributed to the role of gut-microbiota-derived metabolites in the development of dyslipidemia and alterations in lipid metabolism. In this review, we discuss current data involved in these processes and point out the therapeutic potentials. We cover the ability of gut microbiota metabolites to alter lipoprotein lipase action, VLDL secretion, and plasma triglyceride levels, and its effects on reverse cholesterol transport, adipocyte dysfunction, and adipose tissue inflammation. Finally, the current intervention strategies for treatment of obesity and dyslipidemia is addressed with emphasis on the role of gut microbiota metabolites and its ability to predict treatment efficacies.

2 June 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
MZMax S.Z. Zwartjes
Max S.Z. Zwartjes
PJPatrick de Jonge
Patrick de Jonge
ALArnold W. van de Laar
Arnold W. van de Laar
SBSjoerd C. Bruin
Sjoerd C. Bruin
AMAbraham S. Meijnikman
Abraham S. Meijnikman
MNmax Nieuwdorp
max Nieuwdorp
Background: Obesity is an important risk factor for cardiometabolic disease, including dyslipidemia and atherosclerotic cardiovascular disease. Although the role of the liver in dyslipidemia is established, the contribution of adipose tissue is less clear. This study aims to clarify the role of adipose tissue in lipid metabolism and dyslipidemia. Methods: We conducted a cross‐sectional analysis of 125 patients from the BARIA (The Immune System and Microbial Tone in Relation to NAFLD/NASH Before and After Bariatric Surgery in the Morbidly Obese in Amsterdam) longitudinal cohort study undergoing bariatric surgery. Comprehensive phenotyping included fasting untargeted plasma metabolomics, lipid, lipoprotein, adipokine profiling, RNA sequencing, and fecal shotgun metagenomics. Tissue transcriptomic and plasma metabolites were compared between individuals with and without dyslipidemia. Results: Dyslipidemia was present in 43 of 125 individuals (34.4%), with higher triglycerides (1.62 versus 1.24 mmol/L), apoB (apolipoprotein B; 93.15 versus 81.81 mg/dL), and lower high‐density lipoprotein (1.02 versus 1.35 mmol/L) and apoAI (136.40 versus 161.35 mg/dL). Plasma adipokines showed limited differences: leptin concentrations were lower in dyslipidemia in unadjusted analysis but reduced after adjustment for age, sex, and body weight (adjusted P =0.057). RNA sequencing identified altered gene expression of liver, jejunum, visceral and subcutaneous adipose tissue, most pronounced in subcutaneous adipose tissue. Dyslipidemia was associated with adipose tissue pathways related to inflammation, oxidative stress, and adipogenesis. Plasma metabolomics revealed associations with endocannabinoid‐like, secondary bile acid, plasmalogen, butyrate, and sphingolipid metabolites. Gut metagenome analysis found modest differences. Conclusions: Dyslipidemia in obesity is associated with transcriptomic alterations in adipose tissue, including subcutaneous adipose tissue, involving inflammation, oxidative stress, and adipogenesis. These findings support a role of adipose tissue in lipid regulation beyond hepatic pathways.

10 September 2025 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
RFRutger Franken
Rutger Franken
MZMax S.Z. Zwartjes
Max S.Z. Zwartjes
ASAshley Senff
Ashley Senff
BHBarbara A. Hutten
Barbara A. Hutten
MRMaurits De Rotte
Maurits De Rotte
MNmax Nieuwdorp
max Nieuwdorp

16 October 2025 in bioRxiv
Verified
Preprint
Open access
MZMax S.Z. Zwartjes
Max S.Z. Zwartjes
PJPatrick A. de Jonge
Patrick A. de Jonge
ALArnold W. van de Laar
Arnold W. van de Laar
SBSjoerd C. Bruin
Sjoerd C. Bruin
AMAbraham S. Meijnikman
Abraham S. Meijnikman
MNMax Nieuwdorp
Max Nieuwdorp
Background: Obesity is an important risk factor for cardiometabolic disease including dyslipidemia and atherosclerotic cardiovascular disease. While the role of the liver in dyslipidemia is established, the contribution of adipose tissue is less clear. This study aims to clarify the role of adipose tissue in lipid metabolism and its impact on dyslipidemia development. Methods: We conducted a cross-sectional analysis of 125 patients from the BARIA longitudinal cohort study, consisting of patients with obesity undergoing bariatric surgery. Comprehensive phenotyping with fasting untargeted plasma metabolomics and lipid, lipoprotein, adipokine, RNA sequencing, and fecal sample shotgun metagenomic analysis was performed. We then compared tissue transcriptomic and plasma metabolites in individuals with and without dyslipidemia, exploring protective and pathogenic mechanisms. Results: Dyslipidemia was present in 43 patients (34.4%), with elevations in triglycerides, ApoB, and reductions in HDL-C and ApoAI. Plasma adipokines were less reliable markers of dyslipidemia: leptin levels were unexpectedly reduced in dyslipidemia, and after adjusting for gender, age, and body weight, adipokines did not differ between patients with and without dyslipidemia. In relation to plasma lipids or dyslipidemia, RNA sequencing identified altered gene expression of liver, jejunum, visceral and subcutaneous adipose tissue. Adipose tissue of patients with dyslipidemia was characterized by gene alterations of 3 pathways: inflammation, oxidative stress, and adipogenesis. Untargeted plasma metabolomics revealed associations of plasma lipids with endocannabinoid-like, secondary bile acid, plasmalogen, butyrate, and sphingolipid metabolites. Gut metagenome analysis in dyslipidemia found only correlation on bacterial order level. Conclusions: This study provides novel insights into the role of adipose tissue in dyslipidemia of obesity. Our findings highlight the importance of not only visceral, but also subcutaneous adipose tissue in regulating plasma lipids. We found that fasting dyslipidemia associated with adipose tissue inflammation, oxidative stress, and altered adipogenesis, providing new insights into metabolic regulation of plasma lipids beyond hepatic pathways.